-
Chloroquine Diphosphate: Applied Autophagy Assays & Cancer R
2026-05-19
Chloroquine diphosphate enables reproducible modulation of autophagy and robust chemo- and radiosensitization in cancer research workflows. This guide translates the latest mechanistic insights and peer-reviewed protocols into practical, optimization-ready strategies for advanced experimental use.
-
Reelin-SFK Pathway Essential for Ketamine’s Synaptic Actions
2026-05-18
This study identifies synaptic Reelin signaling via Apoer2 and Src family kinases as a critical permissive factor for ketamine-induced antidepressant and synaptic effects. The findings highlight why disruptions in this pathway may underlie nonresponsiveness to ketamine in treatment-resistant depression and suggest new mechanistic targets for research.
-
Targeting CaN/FoxO1/FABP4 to Prevent SERCA2-Induced Atherosc
2026-05-18
This study uncovers how SERCA2 dysfunction accelerates atherosclerosis by activating the calcineurin/FoxO1/FABP4 pathway, leading to foam cell formation in macrophages. Pharmacological inhibition of FABP4 corrects aberrant lipid metabolism, revealing a promising targeted approach for atherosclerosis research.
-
Vemurafenib (PLX4032): System-Level Insights in Melanoma Res
2026-05-17
Explore how Vemurafenib (PLX4032) enables advanced melanoma research by targeting BRAF V600E and dissecting resistance networks. This article provides unique assay guidance and integrates multi-omics breakthroughs to inform experimental design.
-
MLN8237 (Alisertib): Reliable Aurora A Inhibition for Cancer
2026-05-16
This article demonstrates how MLN8237 (Alisertib) (SKU A4110) addresses reproducibility, selectivity, and workflow challenges in cell viability, apoptosis, and tumor inhibition assays. Drawing on peer-reviewed evidence and best-practice workflow guidance, it equips biomedical researchers and lab technicians with scenario-driven insights for robust experimental design.
-
Myriocin: Precision Serine Palmitoyltransferase Inhibitor Wo
2026-05-15
Myriocin enables targeted, reproducible inhibition of sphingolipid biosynthesis, empowering advanced workflows in cancer, metabolic, and cardiovascular research. Explore real-world experimental setups, protocol optimizations, and troubleshooting strategies to maximize assay reliability with APExBIO's high-purity Myriocin.
-
Reelin–Src Pathway Is Essential for Ketamine’s Antidepressan
2026-05-15
This study demonstrates that intact Reelin-Apoer2-Src family kinase (SFK) signaling is required for ketamine-induced synaptic plasticity and behavioral changes in mouse models. The findings offer mechanistic insight into why some patients with treatment-resistant depression do not respond to ketamine, highlighting the importance of baseline NMDA receptor function maintained by Reelin signaling.
-
Y-27632 Dihydrochloride: ROCK Inhibitor Workflows in Stem Ce
2026-05-14
Y-27632 dihydrochloride, a selective ROCK inhibitor from APExBIO, drives reproducible gains in stem cell viability and robust suppression of tumor invasion. This guide delivers actionable protocols, troubleshooting strategies, and key insights from recent iPSC disease modeling breakthroughs.
-
Y-27632 Dihydrochloride: Targeting ROCK1/2 in Barrier and Vi
2026-05-14
Explore how Y-27632 dihydrochloride, a potent ROCK inhibitor, advances research in cytoskeletal dynamics, barrier function, and viral entry. This article uniquely connects molecular mechanism to practical assay design with new evidence from cell junction and infection models.
-
Refining In Vitro Metrics for Evaluating Anti-Cancer Agents
2026-05-13
Schwartz’s dissertation establishes a rigorous framework for differentiating between proliferative arrest and cell death in in vitro anti-cancer drug assays. This method enhances mechanistic understanding of drug responses, improving the translational value of preclinical cancer research.
-
5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole: Precision Tra
2026-05-13
Unlock targeted transcriptional regulation and advanced assay reproducibility with 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB). This guide delivers actionable workflows, troubleshooting insights, and evidence-based applications for DRB in cell biology, virology, and translational research.
-
IRF1-PARP12 Axis Impairs Mitophagy and Drives Cartilage Degr
2026-05-12
This study uncovers how IRF1-driven upregulation of PARP12 impairs PINK1/Parkin-dependent mitophagy in chondrocytes, promoting cartilage degradation in osteoarthritis. The work highlights the mechanistic link between inflammatory signaling, mitochondrial quality control, and cartilage pathology, and demonstrates that XAV-939 can suppress PARP12 and OA progression in both cell and animal models.
-
Radiotherapy Plus PD-1/TIGIT Blockade: CD8+ T Cells Drive Ab
2026-05-12
This study demonstrates that combining radiotherapy with dual PD-1 and TIGIT immune checkpoint blockade generates robust antitumor abscopal effects and durable immune memory through CD8+ T cell activation. The findings clarify the cellular mechanisms behind enhanced tumor control and inform strategies to overcome resistance seen with immunotherapy alone.
-
XAV-939 in Applied Wnt/β-Catenin Research: Protocols & Pitfa
2026-05-11
XAV-939 (NVP-XAV939) stands out for precise, reproducible modulation of the Wnt/β-catenin pathway in cancer, fibrosis, and osteogenic differentiation research. Explore advanced workflows, real-world troubleshooting, and key insights from recent literature to maximize data quality and biological relevance.
-
Temafloxacin: Fluoroquinolone Broad-Spectrum Antibacterial A
2026-05-11
Temafloxacin empowers researchers with flexible, high-precision antibacterial workflows for both standard and intracellular infection models. Its well-characterized activity spectrum and robust pharmacology support advanced applications, particularly in studies of Gram-positive, Gram-negative, and atypical pathogens, including Mycobacterium avium complex.
405 records 8/27 page Previous Next First page 上5页 678910 下5页 Last page